About Us
The Health Thread
Ethical Health Journalism
Live
🌍Urgent Alert: Deano's Pasta Recalls Ravioli Over Hidden Lobster Allergen Risk🌍Saratoga Chips Recall: Undeclared Soy Poses Allergy Risk🌍So Delicious Dairy-Free Frozen Dessert Recall: What Consumers Need to Know About Food Safety🌍Hidden Egg Allergen Prompts Whole Foods Cheese Recall🌍DR Congo Camp Residents Face Dire Conditions, Violence, and Ebola Threat🌍Urgent Alert: Deano's Pasta Recalls Ravioli Over Hidden Lobster Allergen Risk🌍Saratoga Chips Recall: Undeclared Soy Poses Allergy Risk🌍So Delicious Dairy-Free Frozen Dessert Recall: What Consumers Need to Know About Food Safety🌍Hidden Egg Allergen Prompts Whole Foods Cheese Recall🌍DR Congo Camp Residents Face Dire Conditions, Violence, and Ebola Threat
Research Watch
•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs

Disitamab vedotin in urothelial carcinoma patients: a clinical trial perspective from ARON working group.

Researchers

Concetta Calabrò, Francesco Ciccimarra, Anna Milella, Gerardo Cazzato, Mario Della Mura, Loredana Palermo, Jure Murgić, Tibor Szarvas, Kannan Sridharan, Maria Tereza Nieto-Coronel, Aly-Khan A Lalani, Olivier Mukuku, Anas Zayed, Cinthia Gauna, Chiara Paciolla, Raffaella Massafra, Oronzo Brunetti, Veronica Mollica, Francesco Massari, Matteo Santoni, Alessandro Rizzo

Abstract

In recent years, studies have demonstrated that in urothelial carcinoma (UC), the rate of HER-2 protein overexpression (immunohistochemistry 2+ and 3+) ranges from 18.1% to 36%, and the rate of HER-2 gene amplification reaches 10%-23%. The advent of HER-2-targeted antibody-drug conjugates and immune checkpoint inhibitors has reshaped the treatment landscape of advanced urothelial carcinoma. In the current paper, we discuss the role of disitamab vedotin as an innovative anticancer therapy in UC patients, with a specific focus on available evidence and ongoing clinical trials. A literature search of PubMed/MEDLINE, Embase, Scopus, and ClinicalTrials.gov (through May 2026) was performed using the terms 'disitamab vedotin,' 'RC48-ADC,' and 'urothelial carcinoma.' As ADC-based strategies continue to expand in UC, further studies will be needed to better understand how DV should be integrated with other anticancer approaches in this setting, particularly in terms of patient selection and treatment sequencing.
Source: PubMed (PMID: 42829986)View Original on PubMed